Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
COSCIENS Biopharma Inc
T.CSCI
Alternate Symbol(s):
CSCI
Healthcare
Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone...
deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CSCI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(30)
•••
Stinzo
X
View Profile
View Bullboard History
Comment by
Stinzo
on Oct 04, 2024 4:19pm
RE:RE:Why no sharebuyback??
Then it is really beyond my understanding how such a scam can be permissible with the governing structure it has. The board of directors should have fired Gagnon many years ago.
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Oct 04, 2024 3:49pm
New Nature paper on alveolar macrophages and COVID
Perplexity Ai's take: The recent Nature Immunology publication on alveolar macrophages and COVID-19 fits well with Ceapro's recent work on yeast beta glucan (YBG) produced using Pressurized
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(150)
•••
Hopeforthebest
X
View Profile
View Bullboard History
Comment by
Hopeforthebest
on Oct 04, 2024 3:05pm
RE:Why no sharebuyback??
You do realize Stinzo that gagnon is out for only 1 person and that is the person he sees every morning in the mirror.gagnon does not know what the term shareholder values means and by doing something
...more
(13)
•••
jrsloan60
X
View Profile
View Bullboard History
Comment by
jrsloan60
on Oct 04, 2024 1:26pm
RE:RE:RE:Why no sharebuyback??
That sounds exactly right. I wished I could write it as well as you can. He's been promising things since I've been there as a shareholder. And I was there before he started. When they built a
...more
(150)
•••
Hopeforthebest
X
View Profile
View Bullboard History
Comment by
Hopeforthebest
on Oct 04, 2024 12:08pm
RE:RE:Why no sharebuyback??
What gagnon has failed to mentioned that under his leadership he has turned 1000 Zentaris share to less than 2 through several stock devaluations, under his leadership gagnon has drained the bank dry
...more
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Oct 04, 2024 10:28am
Oct. 8
able production of biopolymer aerogels and composites. (614) Tue, October 08 Dockside 9 Technical Session
...more
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Oct 04, 2024 9:35am
RE:Why no sharebuyback??
The company is losing significant money. A lot rode on the pediatric diagnostic trial which could have provided substantial upfront, milestone and royalty payments as they drive to sustainability
...more
(30)
•••
Stinzo
X
View Profile
View Bullboard History
Post by
Stinzo
on Oct 04, 2024 8:57am
Why no sharebuyback??
Company holds more cash then market valuation, that's assuming physical assets are worth 0. Shareholders desperately need some breathing air. It seems to me to be a no brainer, use a few M
...more
(150)
•••
Hopeforthebest
X
View Profile
View Bullboard History
Comment by
Hopeforthebest
on Oct 02, 2024 3:37pm
RE:New Press Release - COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
What is the old say, like minded people tend to floc together. gagnon has surrounded himself with yes men and losers, case in point turpin like gagnon are seeing the fruits of their labour, bankruptcy
...more
(13)
•••
jrsloan60
X
View Profile
View Bullboard History
Comment by
jrsloan60
on Oct 02, 2024 1:10pm
RE:This is amazing.
When I fail I don't seem to make any money. So there's usually a consequence to my failure. But it doesn't look like there is to these CEOs or the people that run these companies. If I
...more
(28)
•••
tigerpro
X
View Profile
View Bullboard History
Comment by
tigerpro
on Oct 02, 2024 11:52am
RE:RE:RE:RE:The Era of Gilles is over
100% agree Ciao.
(1988)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Oct 02, 2024 1:00am
RE:New Press Release - COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
Seems like a trade up. see image....
(1793)
•••
Ciao
X
View Profile
View Bullboard History
Comment by
Ciao
on Oct 01, 2024 6:12pm
RE:RE:RE:The Era of Gilles is over
Boaz, absolutely, Gilles sees no commercial development of the pipeline in the coming years. The so called inflection point with Y-BG complexes as an inhalable therapeutic for IPF (or to treat
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 01, 2024 5:30pm
New Press Release - COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, announced...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments